The prevalence of Mycobacterium tuberculosis and rifampicin-resistance strains using GeneXpert-MTB/RIF assay in Ethiopia: a systematic review and meta-analysis Authors: Mengistu Abayneh, Ahmed Zeynudin, Yared Alemu, Teshome Degefa, Abdulhakim Abamecha, Mulualem Tadesse, Abraham Tamirat Gizaw Published: 2025 ABSTRACT BackgroundThe spread of tuberculosis (TB), including strains resistant to at least rifampicin and/or isoniazid, remains a major public health problem in developing nations, yet few comprehensive and comparative data on TB have been produced. The aim of this systematic review and meta-analysis is to determine the pooled prevalence of TB in general and rifampicin-resistant tuberculosis (RR-TB) among presumptive TB patients across different demographic groups in Ethiopia. A presumptive TB patient is someone who shows symptoms or risk factors suggestive of tuberculosis and therefore requires testing.MethodsFor this systematic reviews and meta-analysis PubMed, and Google Scholar databases were searched. In addition, relevant studies were also searched from the bibliographies of eligible studies and from other meta-analysis studies. A selection and inclusion-exclusion process for the required articles was made as per the study objectives and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and the Joanna Briggs Institute’s (JBI) essential appraisal tools were followed during the entire protocol development. The pooled prevalence of TB in general and RR-TB among different demographic categories was estimated with a random-effects model on Statistical Software Package (STATA) version 14.0.ResultsA total of 39 research articles fulfilled the inclusion criteria for this systematic review and meta-analysis. The overall pooled prevalence estimates of TB in general and RR-TB were 15% (95% CI; 0.13–0.17) and 8% (95% CI; 0.07–0.10), respectively. The pooled prevalence of each pulmonary TB and extrapulmonary TB cases was equally 15%, and the pooled prevalence of RR-TB was 8% and 9%, respectively. The pooled prevalence of TB among male and female was 15%, and 13%, whereas RR-TB was detected in 10% and 9% of the TB cases, respectively. Among adults and children, the pooled prevalence of TB was 15% and 13%, whereas RR-TB was detected in 9% and 8% of the TB cases, respectively. The pooled prevalence of TB among newly diagnosed and previous treated TB cases was 13% and 22%, whereas RR-TB was 7% and 17%, respectively. Among HIV-positive cases, the pooled prevalence of TB was 20%, whereas the RR-TB was detected in 13% of TB-HIV cases.ConclusionThis meta-analysis report concluded that the pooled prevalence of TB in general and RR-TB was high across various demographic categories in Ethiopia. Hence, the finding highlights the need to implement integrated intervention approaches such as early case detection, rapid diagnosis, treatment adherence support, and contact tracing to reduce the continued spreading of TB infections, with an emphasis on reducing the spread of drug- resistant TB strains.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12890-025-04051-8. Introduction Tuberculosis (TB) is one of the most common communicable disease that is mostly caused by infection with the species Mycobacterium tuberculosis (MTB), and usually affects the lungs, but can also affect other parts of the body, especially the lymph nodes [1]. MTB spread from person to person through the air when people with pulmonary TB release the MTB into the air during sneeze, cough, and talking [2, 3]. In many people who have latent TB infection, the MTB remain inactive for a lifetime without causing disease. In others, particularly those living in poverty or with compromised immune systems—such as a high burden of HIV/AIDS—the bacteria become active and cause TB disease [2, 3]. Drug-resistant TB (DR-TB) also poses a growing threat to poor populations, who frequently lack access to the expensive, quality tests needed to identify drug resistance [3, 4]. Despite numerous national and international attempts made to prevent and control TB, the disease remains a major global public health concern, particularly in low- and middle-income countries. For instance, the emergence of COVID-19 pandemic has had a profound impact on global and national tuberculosis programmes, restricting care-seeking, and limiting the availability of care providers and essential diagnostic products [5–7]. According to the World Health Organization’s 2024 Global TB report, in 2023, an estimated 10.8 million people became ill with TB, a slight increase from 10.7 million in 2022, although still much higher than 10.4 million in 2021 and 10.1 million in 2020, reversing a downward trend [8]. The report also found that TB remains a leading infectious killer, responsible for 1.25 million deaths in 2023, including 1.09 million among HIV-negative people and 161 000 among people with HIV. MDR/RR-TB also caused an estimated 150 000 deaths in 2023 [8]. In the WHO African region, TB continues to be a significant public health problem, which accounts for 23% of new TB case and 31% of TB-related deaths, although the region making up only 15% of the world’s population [9]. An estimated 2.5 million people fell ill with TB in the region in 2021, and as many as half-a-million people died due to the disease in the same year [9]. Drug resistant TB, both rifampicin resistant (RR) and multi-drug resistant (MDR), is a growing burden, affecting 450 000 and 77 000 people in the region, respectively [9]. In sub-Saharan African countries, the major challenges in TB screening and diagnosis include a high patient load, limited availability of diagnostic tools such as the GeneXpert MTB/RIF assay, and weak patient and laboratory specimen referral systems [10–12]. COVID-19-related disruptions had also its own impact on the reductions of people newly diagnosed and reported TB cases in this region. In Ethiopia, during the COVID-19 era, the detection rate of all forms of TB reduced by 4%–18% and an 11% decline in total TB notification as compared with the pre-COVID-19 era [13]. So far, in most high-incidence countries, including Ethiopia, TB diagnosis relies on either clinical symptoms or laboratory diagnosis using sputum smear microscopy [14]. Recently, the implementation of the GeneXpert-MTB/RIF assay provides an advantage over smear microscopy in terms of higher sensitivity and specificity, and which brought a solution to detect MTB, including RR cases [11, 15, 16]. However, the adoption of new tools, and the accessibility as well as the challenges with implementing the existing GeneXpert-MTB/RIF assay still persists in all settings with limited resources, which leads to the overall low TB case detections and reporting [11, 16, 17]. Additionally, comprehensive and up-to-date data on the prevalence of DR-TB and TB in general across different demographic groups are essential for revising and strengthening TB prevention and control strategies in Ethiopia. Hence, this review aims to generate the data on the combined prevalence of TB in general, and RR-TB among various populations groups in Ethiopia using data reported from 2016 to 2023, which will have a role in sensitizing the local institutions and policy makers for updating their TB prevention and control strategies. Methodology Data sources and search strategy Strategic searches were conducted on PubMed and Google Scholar to identify published articles related to TB detection among presumptive TB patients using the GeneXpert assay in Ethiopia. The searches were conducted using string words like: “Tuberculosis, Multidrug-Resistant“[Mesh] OR “Tuberculosis, Pulmonary“[Mesh] OR “Mycobacterium tuberculosis“[Mesh] OR “Tuberculosis“[Mesh] OR “Tuberculosis, Extrapulmonary“[Mesh] OR “Drug Resistance“[Mesh] OR “Rifampicin resistance TB” [Mesh] OR “RR-TB” [Mesh] AND “Ethiopia”. The searching process was filtered by free full text, English, year of publication from 2016–2023/10/30. Although, PubMed and Google scholar are the most popular journal databases at which most of the relevant published articles were found, the search process also included bibliographies of the eligible studies and from other meta-analysis studies. We included studies conducted between 2016 and 2023 to ensure that the analysis reflects recent data based on the GeneXpert MTB/RIF assay. This meta-analysis specifically focuses on studies that utilized the GeneXpert assay to detect TB and RR-TB among presumptive TB cases in Ethiopia, as the primary aim of this review is to highlight the significance of the GeneXpert assay in the simultaneous detection of both TB and RR-TB and its overall contribution to TB diagnosis and control. Focusing on GeneXpert-confirmed cases allows for a more accurate estimation of the pooled prevalence of TB and RR-TB, as this assay is the most widely implemented rapid diagnostic tool in Ethiopia and provides standardized, comparable, and reliable results across studies. Articles selection processes and inclusion-exclusion criteria Every phase of the article evaluation and selection process, using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [18] flow diagram, are presented in Fig. 1 below. Cross-sectional and retrospective observational studies conducted in Ethiopia and that reported data on the prevalence of TB cases (whether or not disaggregated by sex (male and female), age group (adults and children), clinical form of TB, and TB/HIV co-infection status) using GeneXpert-MTB/RIF assay, and that had an appropriate study design with clearly described settings and recruitment periods, were included in this systematic review and meta-analysis. Excluded publications comprised case reports, anonymous reports, duplicate publications, and articles available only in abstract form; studies conducted outside of Ethiopia; studies that reported molecular characterization of tuberculosis using non-GeneXpert molecular techniques; studies lacking sufficient data on the outcomes of interest; and previously published systematic reviews. In order to ensure the quality of research, two impartial reviewers (MA and ATG) participated in every phase of the article evaluation process, including screening, eligibility, and inclusion-exclusion. Any disagreements between the reviewers were resolved through discussion.Fig. 1PRISMA flow diagram depicting the selection process of the included articles PRISMA flow diagram depicting the selection process of the included articles Data extraction A pre-designed Excel data extraction sheet was used to systematically extract and organize relevant data from all included studies. The extracted data includes the general characteristics of the studies, like the first author, publication year, study region or area, study or data collection period, study design, study subjects, total sample size, type of sample (pulmonary; sputum and/or extrapulmonary), and data addressing the systematic review and meta-analysis questions, like the numbers of TB-positive cases based on age and gender, clinical TB types (pulmonary or extrapulmonary), the status of TB cases (new or retreated), TB-HIV cases, and the number of isolates reported as rifampicin resistance TB. The data extraction procedure was also carried out twice, independently (first by MA and then by ATG). Study quality and risk of bias assessment To ensure the quality of the included studies and minimize the risk of bias, all articles meeting the inclusion criteria were rigorously evaluated by independent reviewers using the Joanna Briggs Institute (JBI) critical appraisal tools [19] before being included in this systematic review and meta-analysis. Whether the research question is clear and adequate to the study; whether the study design used is appropriate to the set research question; whether descriptions of the setting, including periods of recruitment, and design; and whether the collected data was properly managed and analyzed are some of the criteria used for quality assessment for the included studies. The Cochrane hand book [20], was used as a general guidance for the entire protocol development (planning a review, searching and selecting studies, data collection, risk of bias assessment, a statistical analysis, and interpreting results). In addition, all data extraction procedures were also carried out in duplicate manner using specific, pre-determined data extraction tools. Data analysis The proportional meta-analysis was done using the ‘metaprop’ command on STATA version 14 (STATA Corporation, College Station, TX, USA). The pooled prevalence of TB-positive cases with its 95% confidence interval was calculated from the total sample sizes using the random-effects model, by assuming the true effect size varies between the included studies. The pooled percentage of RR-TB cases was then deduced from the total number of TB-positive cases. In addition, the pooled proportion of TB-HIV cases was calculated from the total HIV-positive cases. For both proportions of TB-positive cases and for RR-TB cases, sub-group meta-analysis was computed with regard to gender, age and clinical types of TB. Sensitivity analysis The goal of the sensitivity analysis was to assess whether the inclusion or exclusion of specific studies influenced the overall results, thereby determining the robustness and reliability of the findings for inclusion in the systematic review and meta-analysis, as well as to determine how much the study outcomes varied across the included studies. Here, a Cochrane’s chi-square (Q)-tests and I2 statistics, and p-values were used to assess the potential presence of heterogeneity across the included studies and significant variation was considered at I2 >50% and p < 0.05 [21]. The presence of potential publication bias across studies was assessed using Egger’s regression asymmetry test and Begg and Mazumdar’s rank correlation test, with a p-value < 0.05 considered statistically significant. Although these tests have limitations when applied to prevalence data, they are widely used in meta-analyses as supplementary tools to detect possible asymmetry in effect estimates. Results Characteristics of studies included The numbers and criteria used to include and exclude the articles are presented in Fig. 1. Through the process, a total of 39 research articles met the inclusion criteria for the final systematic review and meta-analysis. All the included studies were done with a retrospective and prospective cross-sectional study design. Thirteen studies were conducted in the Amhara region, nine studies in Addis Ababa, five in southern Ethiopia, five studies in Oromia, three studies in Tigray, and one study in each of the Gambella, Afar, and Southwest people regions of Ethiopia. One study was conducted at the refugee camps across regions of Ethiopia (Table 1).Table 1Characteristics of included studies on TB using GeneXpert MTB/RIF assay in Ethiopia (2016–2023)Study’s Author, ReferencesStudy RegionStudy YearPublication YearStudy DesignStudy populationsSample sizeProportion of TB positive casesType TB IdentifiedAbay GK, et al. 2020 [22]TigrayJanuary 2015 to 20182020RCSAll presumptive TB patients59441446/5944PTB & EPTBAbayneh M, et al. 2022 [23]Southwest EthiopiaJune to Sept., 20212022CSAll Presumptive TB patients ≥ 5 years42253/422PTB & EPTBAdmassu W, et al. 2022 [24]OromiaMay 2018 to August 20192022RCSAll presumptive TB patients2220206/2220PTB & EPTBAkalu GT, et al. 2022 [25]Addis AbabaOct. 2019 to July 20202022CSAll new presumptive PTB patients21624/216PTB & EPTBAlehegn E, et al. 2023 [26]Addis AbabaFebruary to August 20222023CSAll presumptive EPTB patients30854/308EPTBAndarge DB, et al. 2021 [27]South EthiopiaApril to July 20182021CSPresumptive TB Patients of age ≥ 18 years32198/321PTBArega B, et al. 2019 [28]Addis AbabaMarch 2015 to Oct. 20172019RCSAll TB presumptive patients12,4141876/12,414PTBAraya S, et al. 2020 [29]Addis AbabaJanuary 2016 to Dec. 20182020RCSAll Presumptive TB patients12,6851714/12,685PTBAyalew ML, et al. 2020 [30]AmharaFebruary to May 20192020CSPresumptive children < 15 years38422/384PTBBeza MG, et al. 2017 [31]AmharaFebruary to May 20162022CSTB suspected prisoners > 15 years2659/265PTBDejene TA, et al. 2023 [32]TigrayJanuary 2016 to Dec. 20192023RCSChildren with presumptive TB (< 18 years)7080514/7080PTBDemissie TA, et al. 2021 [33]AmharaOctober to November 20202021RCSAll presumptive PTB patients4109346/4109PTB & EPTBDerbie W, et al. 2016 [34]AmharaNov. 2015 to April 20162016RCSAll presumptive PTB patients1922258/1922PTBDiriba G, et al. 2022 [35]Addis Ababa2014 to 20212022RCSAll presumptive PTB and EPTB patients13,7722347/13,772PTB & EPTBDiriba K, et al. 2021 [36]South EthiopiaJanu 2014 to Dec. 20202021RCSAll Presumptive TB patients17,7452090/17,745PTB & EPTBDiriba K, et al. 2022 [37]South EthiopiaFebruary to July 20212022CSPresumptive TB Patients of age ≥ 18 years384103/384PTBE. Ejeta, et al. 2018 [38]GambellaMay 1–30, 20172018RCSAll Presumptive TB patients995193/995PTBFanosie A, et al. 2016 [39]AmharaMarch to April 20152016CSAll presumptive EPTB patients14137/141EPTBGebrehiwet GB, et al. 2019 [40]AfarNov. 2016 to May 20172019CSAll Presumptive TB patients38494/384PTBGebretsadik D, et al. 2020 [41]AmharaOctober 2018 to Feb. 20192020CSAll Presumptive TB patients42338/423PTBHaile A, et al. 2021 [42]South EthiopiaJanuary 2016 to 20202021RCSAll Presumptive PTB patients3286899/3286PTBJaleta KN, et al. 2017 [43]AmharaJanuary 2013 to Aug. 20152017RCSAll Presumptive TB patients1820448/1820PTBKassa M, et al. 2022 [44]Addis AbabaJanuary to July 20192022CSAll presumptive PTB patients43627/436PTBKelecha WT, et al. 2021 [45]OromiaOctober 2020 to Feb. 20212021CSAll Presumptive TB patients30146/301PTB & EPTBKumbi H, et al. 2023 [46]OromiaMay 2022 to August 302023CSAll presumptive TB lymphadenitis291138/291EPTBMeaza A, et al. 2023 [47]Refugee campsFebruary to August 20212023CSAll Presumptive TB in refugees61078/610PTBMetaferia Y, et al. 2018 [48]AmharaMarch to June 20172018CSPresumptive EPTB cases > 18 years35331/353EPTBMohammed H, et al. 2022 [49]Addis AbabaJuly 2019 to Dec. 20202022CSAll presumptive PTB patients1,853163/1489PTBMulu W, et al. 2017 [50]AmharaSep. 2014 to March 20152021CSAll Presumptive TB patients505117/505PTB & EPTBSelfegna S, et al. 2022 [51]AmharaDec. 2019 to June 20202022CSPresumptive TB patients > 16 years17019/170PTBSimieneh A, et al. 2022 [52]OromiaApril to October 20192022CSAll Presumptive EPTB patients14716/147EPTBSinshaw W, et al. 2022 [53]Addis AbabaAugust 2017 to Jan. 20182022CSAll presumptive PTB Patients41827/418PTBTedla E, et al. 2020 [54]AmharaFebruary to April 20182020CSAll presumptive EPTB patients33779/337EPTBTemesgen E, et al. 2021 [55]Addis AbabaFebruary to June 20202021CSChronic psychotic disorder ≥ 18 years25027/250PTBToru M, et al. 2022 [56]AmharaFebruary to June 20192022CSAll presumptive PTB HIV positives11213/112PTBWasihun AG, et al. 2020 [57]TigrayJanuary 2016 to Dec. 20192020RCSPresumptive TB patients ≥ 18 years30,3002387/30,300PTBWasihun AG, et al. 2021 [58]Amhara2015 to 20192021RCSAll Presumptive TB patients26,6562941/26,656PTBWorku M, et al. 2019 [59]South EthiopiaMarch 2012 to April 20142019CSAll Presumptive TB Patients1798217/1798PTBZewdie O, et al. 2020 [60]OromiaNov. 2015 to April 20162020RCSAll presumptive PTB patients2300491/2300PTBNB The prevalence presented in this study indicates the proportion of TB and RR-TB among presumptive TB patients attending health facilities in Ethiopia, CS Cross-sectional, RCS Retrospective cross-sectional Table 1Characteristics of included studies on TB using GeneXpert MTB/RIF assay in Ethiopia (2016–2023)Study’s Author, ReferencesStudy RegionStudy YearPublication YearStudy DesignStudy populationsSample sizeProportion of TB positive casesType TB IdentifiedAbay GK, et al. 2020 [22]TigrayJanuary 2015 to 20182020RCSAll presumptive TB patients59441446/5944PTB & EPTBAbayneh M, et al. 2022 [23]Southwest EthiopiaJune to Sept., 20212022CSAll Presumptive TB patients ≥ 5 years42253/422PTB & EPTBAdmassu W, et al. 2022 [24]OromiaMay 2018 to August 20192022RCSAll presumptive TB patients2220206/2220PTB & EPTBAkalu GT, et al. 2022 [25]Addis AbabaOct. 2019 to July 20202022CSAll new presumptive PTB patients21624/216PTB & EPTBAlehegn E, et al. 2023 [26]Addis AbabaFebruary to August 20222023CSAll presumptive EPTB patients30854/308EPTBAndarge DB, et al. 2021 [27]South EthiopiaApril to July 20182021CSPresumptive TB Patients of age ≥ 18 years32198/321PTBArega B, et al. 2019 [28]Addis AbabaMarch 2015 to Oct. 20172019RCSAll TB presumptive patients12,4141876/12,414PTBAraya S, et al. 2020 [29]Addis AbabaJanuary 2016 to Dec. 20182020RCSAll Presumptive TB patients12,6851714/12,685PTBAyalew ML, et al. 2020 [30]AmharaFebruary to May 20192020CSPresumptive children < 15 years38422/384PTBBeza MG, et al. 2017 [31]AmharaFebruary to May 20162022CSTB suspected prisoners > 15 years2659/265PTBDejene TA, et al. 2023 [32]TigrayJanuary 2016 to Dec. 20192023RCSChildren with presumptive TB (< 18 years)7080514/7080PTBDemissie TA, et al. 2021 [33]AmharaOctober to November 20202021RCSAll presumptive PTB patients4109346/4109PTB & EPTBDerbie W, et al. 2016 [34]AmharaNov. 2015 to April 20162016RCSAll presumptive PTB patients1922258/1922PTBDiriba G, et al. 2022 [35]Addis Ababa2014 to 20212022RCSAll presumptive PTB and EPTB patients13,7722347/13,772PTB & EPTBDiriba K, et al. 2021 [36]South EthiopiaJanu 2014 to Dec. 20202021RCSAll Presumptive TB patients17,7452090/17,745PTB & EPTBDiriba K, et al. 2022 [37]South EthiopiaFebruary to July 20212022CSPresumptive TB Patients of age ≥ 18 years384103/384PTBE. Ejeta, et al. 2018 [38]GambellaMay 1–30, 20172018RCSAll Presumptive TB patients995193/995PTBFanosie A, et al. 2016 [39]AmharaMarch to April 20152016CSAll presumptive EPTB patients14137/141EPTBGebrehiwet GB, et al. 2019 [40]AfarNov. 2016 to May 20172019CSAll Presumptive TB patients38494/384PTBGebretsadik D, et al. 2020 [41]AmharaOctober 2018 to Feb. 20192020CSAll Presumptive TB patients42338/423PTBHaile A, et al. 2021 [42]South EthiopiaJanuary 2016 to 20202021RCSAll Presumptive PTB patients3286899/3286PTBJaleta KN, et al. 2017 [43]AmharaJanuary 2013 to Aug. 20152017RCSAll Presumptive TB patients1820448/1820PTBKassa M, et al. 2022 [44]Addis AbabaJanuary to July 20192022CSAll presumptive PTB patients43627/436PTBKelecha WT, et al. 2021 [45]OromiaOctober 2020 to Feb. 20212021CSAll Presumptive TB patients30146/301PTB & EPTBKumbi H, et al. 2023 [46]OromiaMay 2022 to August 302023CSAll presumptive TB lymphadenitis291138/291EPTBMeaza A, et al. 2023 [47]Refugee campsFebruary to August 20212023CSAll Presumptive TB in refugees61078/610PTBMetaferia Y, et al. 2018 [48]AmharaMarch to June 20172018CSPresumptive EPTB cases > 18 years35331/353EPTBMohammed H, et al. 2022 [49]Addis AbabaJuly 2019 to Dec. 20202022CSAll presumptive PTB patients1,853163/1489PTBMulu W, et al. 2017 [50]AmharaSep. 2014 to March 20152021CSAll Presumptive TB patients505117/505PTB & EPTBSelfegna S, et al. 2022 [51]AmharaDec. 2019 to June 20202022CSPresumptive TB patients > 16 years17019/170PTBSimieneh A, et al. 2022 [52]OromiaApril to October 20192022CSAll Presumptive EPTB patients14716/147EPTBSinshaw W, et al. 2022 [53]Addis AbabaAugust 2017 to Jan. 20182022CSAll presumptive PTB Patients41827/418PTBTedla E, et al. 2020 [54]AmharaFebruary to April 20182020CSAll presumptive EPTB patients33779/337EPTBTemesgen E, et al. 2021 [55]Addis AbabaFebruary to June 20202021CSChronic psychotic disorder ≥ 18 years25027/250PTBToru M, et al. 2022 [56]AmharaFebruary to June 20192022CSAll presumptive PTB HIV positives11213/112PTBWasihun AG, et al. 2020 [57]TigrayJanuary 2016 to Dec. 20192020RCSPresumptive TB patients ≥ 18 years30,3002387/30,300PTBWasihun AG, et al. 2021 [58]Amhara2015 to 20192021RCSAll Presumptive TB patients26,6562941/26,656PTBWorku M, et al. 2019 [59]South EthiopiaMarch 2012 to April 20142019CSAll Presumptive TB Patients1798217/1798PTBZewdie O, et al. 2020 [60]OromiaNov. 2015 to April 20162020RCSAll presumptive PTB patients2300491/2300PTBNB The prevalence presented in this study indicates the proportion of TB and RR-TB among presumptive TB patients attending health facilities in Ethiopia, CS Cross-sectional, RCS Retrospective cross-sectional Characteristics of included studies on TB using GeneXpert MTB/RIF assay in Ethiopia (2016–2023) NB The prevalence presented in this study indicates the proportion of TB and RR-TB among presumptive TB patients attending health facilities in Ethiopia, CS Cross-sectional, RCS Retrospective cross-sectional Regarding the TB type, pulmonary TB was reported in 33 studies, and 14 studies found with extrapulmonary TB. Twenty-four studies involved pulmonary (sputum) samples for the detection of MTB; six research studies used only extra-pulmonary samples, and nine studies used both pulmonary and extra-pulmonary samples for the detection of MTB. Thirty involved both adults and children, 7 involved adults only, and 2 involved children only. However, among the 30 studies with both populations, 6 lacked disaggregated data for adults and 9 lacked disaggregated data for children. Moreover, some studies reported data on both newly diagnosed and previously treated TB patients, leading to overlap in the count of studies between these two categories. Specifically, 25 studies included data on previously treated TB patients, while 27 studies included data on newly diagnosed TB cases. Fifteen studies included in this review were retrospective in design. The details on the included studies is presented below in Table 1. Description of outcome measurements and findings In this review, the pooled prevalence of TB-positive cases in general and RR-TB cases among different population groups were calculated. All studies that reported data on the proportion of TB-positive cases, whether or not they included additional categorical data such as sex, age, or TB/HIV co-infection status, and that utilized the GeneXpert-MTB/RIF assay were included in this meta-analysis. As shown in Table 2, most of the included studies reported complete and clearly defined data on sex, age, TB/HIV co-infection status, and clinical forms of TB. Accordingly, the prevalence of TB among male and female patients was pooled from 33 studies, and among adults and children, it was pooled from 31 to 22 studies, respectively. Among newly diagnosed and previously treated TB cases, the pooled prevalence of TB was aggregated from 27 to 25 studies, respectively (Table 2).Table 2Proportions of TB in general and RR-TB in the included studies utilizing GeneXpert MTB/RIF assay in EthiopiaStudy’s Author, ReferencesTotal proportion of TB positive casesTotal RR-TB casesProportions TB and RR-TB among different population groupsTB-HIV co-infected casesRR among TB-HIV co-infected casesAdultChildrenMaleFemaleNewly diagnosed TB casesPrevious treated TB casesTBRR-TBTBRR-TBTBRR-TBTBRR-TBTBRR-TBTBRR-TBGebretsadik D, et al. 2020 [41]38/4232/3834/3722/344/51─24/253ND14/170─32/3941/326/291/63/14─Wasihun AG, et al. 2021 [58]2941/26,656245/29412747/24,116231/2747194/254014/1941653/14,624ND1288/12,032─2093/20,273154/2093848/6383─357/2826─Mulu W et al. 2017 [50]117/50512/117101/443─16/623/1674/2658/7443/2404/4376/3725/7641/1327/4130/1835/30Diriba K et al. 2022 [37]103/384─103/384───73/247─30/137────8/29─Diriba G, et al., 2022 [35]2347/13 772233/23472270/12,660225/227073/10548/731486/8223125/1486857/5549108/8571576/9767105/1576605/2844112/623133/88915/133Diriba K, et al. 2021 [36]2090/17,745107/20901958/16,591103/1958132/11544/1321224/11,02974/1224866/671633/8661940/13,49462/1940150/425145/150160/43661/160Admassu W et al. 2022 [24]206/22207/206171/16655/17135/5552/35────187/2150─15/361/1533/961/33Wasihun AG et al. 2020 [57]2387/30,300215/23872387/30,300215/2387──1457/17,471125/1457930/12,82990/9302195/28,996176/2195190/130439/190288/267517/288Andarge DB et al.2021 [27]98/3214/9898/3214/98──────1/76─3/22──Selfegna S, et al. 2022 [51]19/1703/1919/1703/19──12//1102/127/601/72/134─17/363/1912/582/12Jaleta KN et al. 2017 [43]448/182071/448329/170370/32919/1171/19260/107845/260188/74226/18877/30510/77371/1,51561/37175/31514/75Demissie TA et al. 2021 [33]346/410915/346314/3834─32/275─176/214810/176170/19615/170314/402713/31434/822/3448/4012/48Derbie W et al. 2016 [34]258/192224/258221/1380─37/542─151/100517/151107/9177/107─10/103─14/155108/8888/108Kelecha WT et al. 2021 [45]46/3012/4640/2382/406/63─28/1651/2818/1361/1833/247─13/542/134/27─E. Ejeta et al. 2018 [38]193/9959/193173/7259/16720/174─120/5414/12062/3973/6291/4652/8845/2056/4533/935/31Arega B, et al. 2019 [28]1876/12,414186/18761775/11,672178/1775101/7428/101────1657/10,538126/1657219/187660/219─17/117Kumbi H et al. 2023 [46]138/2919/138───────────16/6815/30─Mohammed H et al. 2022 [49]163/1489─────────────9/135─Haile A, et al. 2021 [42]899/3286137/899811/2990─80/296─500/1787─399/1479─660/2898121/826──41/142─Fanosie A, et al.2016 [39]37/141─34/112─3/29─20/74─17/67─37/141───12/37─Simieneh A, et al. 2022 [52]16/147──2/34──────────4/23─Abayneh M, et al. 2022 [23]53/4223/5348/383─5/39─37/253─14/43─────14/43─Akalu GT, et al. 2022 [25]24/21624/216────11/119─10/49─16/16716/1678;498/4910/49─Dejene TA, et al. 2023 [32]514/708056/514───56/514257/396030/25730/36426/257477/682847/47737/2529/3730/3644/30Sinshaw W, et al. 2022 [53]27/418─27/398───19/187───24/3692/273/491/33/57─Worku M, et al. 2019 [59]217/1798─194/1691─19/100─114/987─6/28─141/1072─60/435───Meaza A et al. 2023 [47]78/610─77/541─4/69─52/275─7/63─67/549─14/61─7/63─Temesgen E et al. 2021 [55]27/250─27/250───19/171─7/45───ND─7/45─Gebrehiwet GB et al. 2019 [40]94/3844/9490/265───44/189─12/31─67/321─27/63─12/31─Ayalew ML et al.2020 [30]22/3842/22───2/2214/196───────6/41─Kassa M, et al. 2022 [44]27/4362/2724/397─3/39─16/224─10/130─24/386─3/50─10/130─Toru M, et al. 2022 [56]13/1123/1313/105───6/68─13/112─────13/112─Beza MG, et al. 2017 [31]9/2651/9────9/263───────3/7─Metaferia Y, et al. 2018 [48]31/353─────15/185───25/321─6/32───Araya S, et al. 2020 [29]1714/12,685169/17141445/11,458141/1445269/122728/2691064/7040102/1064128/77567/6501415/10,772118/1415299/191351/299128/77516/128Tedla E, et al. 2020 [54]79/337─77/331─2/6─51/197─────────Abay GK, et al. 2020 [22]1446/5944132/14461402/5708129/140244/2363/44850/345571/850171/51361/5961385/5733129/138561/2113/61171/51326/171Zewdie O., et al.2020 [60]491/2300127/491443/2004119/44348/2968/48260/115684/260─43/231228/161420/228263/686107/263──Alehegn E., et al. 2023 [26]54/3081/5451/295─3/13─28/148─10/29─37/276─17/32─10/29─ NB “─”: Not reported categorically, TB Tuberculosis, RR-TB Rifampicin resistance tuberculosis Table 2Proportions of TB in general and RR-TB in the included studies utilizing GeneXpert MTB/RIF assay in EthiopiaStudy’s Author, ReferencesTotal proportion of TB positive casesTotal RR-TB casesProportions TB and RR-TB among different population groupsTB-HIV co-infected casesRR among TB-HIV co-infected casesAdultChildrenMaleFemaleNewly diagnosed TB casesPrevious treated TB casesTBRR-TBTBRR-TBTBRR-TBTBRR-TBTBRR-TBTBRR-TBGebretsadik D, et al. 2020 [41]38/4232/3834/3722/344/51─24/253ND14/170─32/3941/326/291/63/14─Wasihun AG, et al. 2021 [58]2941/26,656245/29412747/24,116231/2747194/254014/1941653/14,624ND1288/12,032─2093/20,273154/2093848/6383─357/2826─Mulu W et al. 2017 [50]117/50512/117101/443─16/623/1674/2658/7443/2404/4376/3725/7641/1327/4130/1835/30Diriba K et al. 2022 [37]103/384─103/384───73/247─30/137────8/29─Diriba G, et al., 2022 [35]2347/13 772233/23472270/12,660225/227073/10548/731486/8223125/1486857/5549108/8571576/9767105/1576605/2844112/623133/88915/133Diriba K, et al. 2021 [36]2090/17,745107/20901958/16,591103/1958132/11544/1321224/11,02974/1224866/671633/8661940/13,49462/1940150/425145/150160/43661/160Admassu W et al. 2022 [24]206/22207/206171/16655/17135/5552/35────187/2150─15/361/1533/961/33Wasihun AG et al. 2020 [57]2387/30,300215/23872387/30,300215/2387──1457/17,471125/1457930/12,82990/9302195/28,996176/2195190/130439/190288/267517/288Andarge DB et al.2021 [27]98/3214/9898/3214/98──────1/76─3/22──Selfegna S, et al. 2022 [51]19/1703/1919/1703/19──12//1102/127/601/72/134─17/363/1912/582/12Jaleta KN et al. 2017 [43]448/182071/448329/170370/32919/1171/19260/107845/260188/74226/18877/30510/77371/1,51561/37175/31514/75Demissie TA et al. 2021 [33]346/410915/346314/3834─32/275─176/214810/176170/19615/170314/402713/31434/822/3448/4012/48Derbie W et al. 2016 [34]258/192224/258221/1380─37/542─151/100517/151107/9177/107─10/103─14/155108/8888/108Kelecha WT et al. 2021 [45]46/3012/4640/2382/406/63─28/1651/2818/1361/1833/247─13/542/134/27─E. Ejeta et al. 2018 [38]193/9959/193173/7259/16720/174─120/5414/12062/3973/6291/4652/8845/2056/4533/935/31Arega B, et al. 2019 [28]1876/12,414186/18761775/11,672178/1775101/7428/101────1657/10,538126/1657219/187660/219─17/117Kumbi H et al. 2023 [46]138/2919/138───────────16/6815/30─Mohammed H et al. 2022 [49]163/1489─────────────9/135─Haile A, et al. 2021 [42]899/3286137/899811/2990─80/296─500/1787─399/1479─660/2898121/826──41/142─Fanosie A, et al.2016 [39]37/141─34/112─3/29─20/74─17/67─37/141───12/37─Simieneh A, et al. 2022 [52]16/147──2/34──────────4/23─Abayneh M, et al. 2022 [23]53/4223/5348/383─5/39─37/253─14/43─────14/43─Akalu GT, et al. 2022 [25]24/21624/216────11/119─10/49─16/16716/1678;498/4910/49─Dejene TA, et al. 2023 [32]514/708056/514───56/514257/396030/25730/36426/257477/682847/47737/2529/3730/3644/30Sinshaw W, et al. 2022 [53]27/418─27/398───19/187───24/3692/273/491/33/57─Worku M, et al. 2019 [59]217/1798─194/1691─19/100─114/987─6/28─141/1072─60/435───Meaza A et al. 2023 [47]78/610─77/541─4/69─52/275─7/63─67/549─14/61─7/63─Temesgen E et al. 2021 [55]27/250─27/250───19/171─7/45───ND─7/45─Gebrehiwet GB et al. 2019 [40]94/3844/9490/265───44/189─12/31─67/321─27/63─12/31─Ayalew ML et al.2020 [30]22/3842/22───2/2214/196───────6/41─Kassa M, et al. 2022 [44]27/4362/2724/397─3/39─16/224─10/130─24/386─3/50─10/130─Toru M, et al. 2022 [56]13/1123/1313/105───6/68─13/112─────13/112─Beza MG, et al. 2017 [31]9/2651/9────9/263───────3/7─Metaferia Y, et al. 2018 [48]31/353─────15/185───25/321─6/32───Araya S, et al. 2020 [29]1714/12,685169/17141445/11,458141/1445269/122728/2691064/7040102/1064128/77567/6501415/10,772118/1415299/191351/299128/77516/128Tedla E, et al. 2020 [54]79/337─77/331─2/6─51/197─────────Abay GK, et al. 2020 [22]1446/5944132/14461402/5708129/140244/2363/44850/345571/850171/51361/5961385/5733129/138561/2113/61171/51326/171Zewdie O., et al.2020 [60]491/2300127/491443/2004119/44348/2968/48260/115684/260─43/231228/161420/228263/686107/263──Alehegn E., et al. 2023 [26]54/3081/5451/295─3/13─28/148─10/29─37/276─17/32─10/29─ NB “─”: Not reported categorically, TB Tuberculosis, RR-TB Rifampicin resistance tuberculosis Proportions of TB in general and RR-TB in the included studies utilizing GeneXpert MTB/RIF assay in Ethiopia NB “─”: Not reported categorically, TB Tuberculosis, RR-TB Rifampicin resistance tuberculosis The pooled prevalence of TB among different groups In this meta-analysis, the pooled prevalence of TB in general was computed from 39 included studies. There was significant heterogeneity (I2 = 98.86%; p < 0.001) among studies, with the overall pooled prevalence of TB being 15% (95% CI: 0.13–0.17) and the prevalence of TB ranging from 3% (95% CI: 0.02–0.06) to 47% (95% CI: 0.42–0.53) among individual studies (Fig. 2). Among the reviewed articles, more than 20% prevalence of TB cases was reported in eleven articles [22, 27, 29, 37, 39, 40, 42, 43, 46, 50, 60], of which the highest TB prevalence rate of 47.0% was reported by Kumbi et al. [46]. (Fig. 2).Fig. 2Proportional meta-analysis of the pooled prevalence of TB from studies utilizing the GeneXpert MTB/RIF assay in Ethiopia Proportional meta-analysis of the pooled prevalence of TB from studies utilizing the GeneXpert MTB/RIF assay in Ethiopia According to this meta-analysis, the percentage of TB cases in Ethiopia varied across different demographic categories. For each categorical meta-analysis, a random-effects model was employed to calculate the pooled prevalence of TB-positive cases, assuming that the true effect size varies among the included studies. Out of the 39 publications, thirty-three studies [22, 23, 25, 26, 29–45, 47, 48, 50, 51, 53–60] categorically reported the prevalence of TB among male and female patients. As indicated in Table 3, the combined prevalence of TB among patients who were male was 15% (95% CI: 0.13–0.17; I2 = 98.29%, p < 0.001) and for female patients it was 13% (95% CI: 0.11–0.15; I2 = 97.49%, p < 0.001). The prevalence of TB throughout the included studies exhibited significant heterogeneity (I2 >75%; p < 0.001), even though there were no differences between the two groups (p = 0.319) (Table 3).Table 3A summary of the pooled prevalence of TB among different groups of people utilizing GeneXpert- MTB/RIF assay in Ethiopia (2016–2023)CategoriesThe ranges of TB proportion in each studyThe pooled proportion (95%CI)Heterogeneity between the studies I2 = %, p = valueHeterogeneity between the groups p = valueMale0.03 to 0.300.15 (0.13–0.17)I2 = 98.29%, P < 0.001P = 0.319Female0.03 to 0.270.13 (0.11–0.15)I2 = 97.47%, P < 0.001Adult0.03 to 0.270.15 (0.13–0.17)I2 = 98.90%, P < 0.001P = 0.308Children0.06 to 0.330.13 (0.10–0.16)I2 = 92.78%, P < 0.001PTB0.06 to 0.270.15 (0.13–0.17)I2 = 99.10%, P < 0.001P = 0.823EPTB0.01 to 0.470.15 (0.09–0.23)I2 = 99.34%, P < 0.001New TB Cases0.01 to 0.260.13 (0.11–0.15)I2 = 98.90%, P < 0.001P < 0.001Previous treated TB case0.04 to 0.530.22 (0.17–0.26)I2 = 98.14%, P < 0.001TB-HIV0.05 to 0.630.20 (0.16–0.23)I2 = 93.09%, P < 0.001 Table 3A summary of the pooled prevalence of TB among different groups of people utilizing GeneXpert- MTB/RIF assay in Ethiopia (2016–2023)CategoriesThe ranges of TB proportion in each studyThe pooled proportion (95%CI)Heterogeneity between the studies I2 = %, p = valueHeterogeneity between the groups p = valueMale0.03 to 0.300.15 (0.13–0.17)I2 = 98.29%, P < 0.001P = 0.319Female0.03 to 0.270.13 (0.11–0.15)I2 = 97.47%, P < 0.001Adult0.03 to 0.270.15 (0.13–0.17)I2 = 98.90%, P < 0.001P = 0.308Children0.06 to 0.330.13 (0.10–0.16)I2 = 92.78%, P < 0.001PTB0.06 to 0.270.15 (0.13–0.17)I2 = 99.10%, P < 0.001P = 0.823EPTB0.01 to 0.470.15 (0.09–0.23)I2 = 99.34%, P < 0.001New TB Cases0.01 to 0.260.13 (0.11–0.15)I2 = 98.90%, P < 0.001P < 0.001Previous treated TB case0.04 to 0.530.22 (0.17–0.26)I2 = 98.14%, P < 0.001TB-HIV0.05 to 0.630.20 (0.16–0.23)I2 = 93.09%, P < 0.001 A summary of the pooled prevalence of TB among different groups of people utilizing GeneXpert- MTB/RIF assay in Ethiopia (2016–2023) Of the papers that were included in the meta-analysis, twenty-three studies [22–24, 26, 28, 29, 33–36, 38, 39, 41–45, 47, 50, 54, 58–60] described the prevalence of TB in children, and thirty-one research publications [22–24, 26–29, 33–45, 47, 50, 51, 53–60] reported the prevalence of TB in adults. Accordingly, the prevalence of TB among adults varied from 3% (95% CI: 0.02–0.06) to 27% (95% CI: 0.26–0.29), with a pooled prevalence of 15% (95% CI: 0.13–0.17; I2 = 98.90%, p < 0.001). Additionally, it was discovered that the combined prevalence of TB in children was 13% (95% CI: 0.10–0.16) and the frequency of TB varied significantly between studies, ranging from 6% (95% CI: 0.05–0.09) to 33% (95% CI: 0.10–0.70) (I2 = 92.78%, p < 0.001) (Table 3). Regarding clinical forms of TB, EPTB prevalence was aggregated from 14 distinct research findings [22–24, 26, 33, 35, 36, 39, 45, 46, 48, 50, 52, 54], whereas PTB prevalence was combined from the data in 28 individual studies [22–25, 27–29, 32–38, 41–43, 45, 47, 49–51, 53, 55, 57–60]. The combined prevalence of EPTB was found to be 15% (95% CI; 0.09–0.23; I2 = 94.34%, p < 0.001), and in the same way, the combined prevalence of PTB was 15% (95% CI; 0.13–0.17; I2 = 99.10%, p < 0.001). Despite no significant difference in the occurrence of PTB and EPTB (p = 0.823), the prevalence estimates among the individual studies in both groups showed substantial heterogeneity (I2 >75%; p < 0.001) (Table 3). Regarding the state of TB cases (new or re-treated), the pooled prevalence of TB among cases that were newly diagnosed was determined based on data from 27 studies [22, 24–26, 28, 29, 32, 33, 35, 36, 38–45, 47, 48, 50, 51, 53, 57–60] was 13% (95% CI: 0.11–0.15; I2 = 98.90%, p < 0.001). The pooled prevalence of TB among previously treated cases was 22% (95% CI: 0.17–0.26; I2 = 98.14%, p < 0.001), based on the data from 25 research studies [22, 24–26, 28, 29, 32, 33, 35, 36, 38, 40, 41, 43–45, 47, 48, 50, 51, 53, 57–60]. The occurrence of TB significantly varied across the groups and among individual studies (p < 0.001 and I2 >75%) (Table 3). The pooled prevalence of TB-HIV Co-infections In this meta-analysis, the pooled prevalence of TB-HIV co-infections was computed from the data extracted from thirty-three studies [22–26, 29–47, 49–53, 55–58] (Fig. 3). There was significant heterogeneity among individual studies (I2 = 93.09%; p < 0.001), with the pooled prevalence of TB among HIV positive cases being 20% (95% CI: 0.16–0.23) and the prevalence of TB-HIV co-infections ranging from 5% (% CI: 0.02–0.14) to 63% (% CI: 0.41–0.84) across individual studies (Table 3; Fig. 3).Fig. 3Pooled prevalence of TB–HIV co-infection from studies utilizing the GeneXpert MTB/RIF assay in Ethiopia Pooled prevalence of TB–HIV co-infection from studies utilizing the GeneXpert MTB/RIF assay in Ethiopia The pooled prevalence estimates of RR-TB Out of the 39 research publications that provided the data on TB prevalence using the GeneXpert-MTB/RIF assay, thirty (30) research publications provide the data on the prevalence of RR-TB across various demographic categories in Ethiopia. As shown in the forest plot (Fig. 4) below, the overall pooled prevalence estimate of RR-TB was 8% (95% CI: 0.07–0.10). The prevalence varied greatly throughout individual studies, ranging from 2% (95% CI: 0.00–0.10) to 26% (95% CI: 0.22–0.30) (I2 = 88.87%; p < 0.001) (Fig. 4; Table 2).Fig. 4Pooled prevalence of RR-TB from studies utilizing the GeneXpert MTB/RIF assay in Ethiopia Pooled prevalence of RR-TB from studies utilizing the GeneXpert MTB/RIF assay in Ethiopia In this meta-analysis, a random-effects model was employed to calculate the pooled prevalence of RR-TB cases among each category. Accordingly, the prevalence of RR-TB in both male and female TB cases was compiled from the findings of 14 research publications [22, 29, 32–36, 38, 43, 45, 50, 51, 57, 60]. As a result, among male TB cases, the pooled prevalence of RR-TB was 10% (95% CI: 0.07–0.13), and the prevalence varied greatly amongst studies, ranging from 3% (95% CI: 0.01–0.08) to 32% (95% CI: 0.27–0.38; I2 = 90.79%, p < 0.001). The pooled prevalence of RR-TB among female TB cases was 9% (95% CI: 0.06–0.11; I2 = 85.77%, p < 0.001), with significant variation among the individual studies (Table 4).Table 4Pooled estimates of RR-TB cases in different groups of people that reported from studies utilizing GeneXpert- MTB/RIF assay in Ethiopia (2016–2023)CategoriesThe ranges of RR-TB in each studyThe pooled proportion (95%CI)Heterogeneity between the studies I2 = %, p = valueHeterogeneity between the groups p = valueMale0.03 to 0.320.10 (0.07–0.13)I2 = 90.79%, P < 0.001P = 0.554Female0.03 to 0.190.09 (0.06–0.11)I2 = 85.77%, P < 0.001Adult0.03 to 0.270.09 (0.07–0.11)I2 = 93.33%, P < 0.001P = 0.730Children0.03 to 0.190.08 (0.06–0.11)I2 = 40.15%, P = 0.080PTB0.02 to 0.160.08 (0.07–0.10)I2 = 81.97%, P < 0.001P = 0.343EPTB0.03 to 0.110.09 (0.07–0.11)I2 = 0.00%, P = 0.530New TB Cases0.01 to 0.150.07 (0.06–0.09)I2 = 88.27%, P < 0.001P < 0.001Previous treated TB case0.05 to 0.410.17 (0.13–0.22)I2 = 82.44%, P < 0.001TB-HIV0.03 to 0.380.13 (0.08–0.18)I2 = 85.34%, P < 0.001 Table 4Pooled estimates of RR-TB cases in different groups of people that reported from studies utilizing GeneXpert- MTB/RIF assay in Ethiopia (2016–2023)CategoriesThe ranges of RR-TB in each studyThe pooled proportion (95%CI)Heterogeneity between the studies I2 = %, p = valueHeterogeneity between the groups p = valueMale0.03 to 0.320.10 (0.07–0.13)I2 = 90.79%, P < 0.001P = 0.554Female0.03 to 0.190.09 (0.06–0.11)I2 = 85.77%, P < 0.001Adult0.03 to 0.270.09 (0.07–0.11)I2 = 93.33%, P < 0.001P = 0.730Children0.03 to 0.190.08 (0.06–0.11)I2 = 40.15%, P = 0.080PTB0.02 to 0.160.08 (0.07–0.10)I2 = 81.97%, P < 0.001P = 0.343EPTB0.03 to 0.110.09 (0.07–0.11)I2 = 0.00%, P = 0.530New TB Cases0.01 to 0.150.07 (0.06–0.09)I2 = 88.27%, P < 0.001P < 0.001Previous treated TB case0.05 to 0.410.17 (0.13–0.22)I2 = 82.44%, P < 0.001TB-HIV0.03 to 0.380.13 (0.08–0.18)I2 = 85.34%, P < 0.001 Pooled estimates of RR-TB cases in different groups of people that reported from studies utilizing GeneXpert- MTB/RIF assay in Ethiopia (2016–2023) After combining data from 15 different research articles [22, 24, 27, 28, 28, 29, 35, 36, 38, 38, 41, 43, 45, 45, 51, 57, 58, 60], the prevalence of RR-TB among adults with TB cases was determined to be 9% (95% CI: 0.07–0.11), with a significant variation of the prevalence across the included studies (I2 = 93.33%, p < 0.001). Furthermore, the pooled prevalence of RR-TB among children with TB cases computed from 11 research publications [22, 24, 28, 29, 32, 35, 36, 43, 50, 58, 60], and the pooled prevalence of RR-TB was found in 8% (95% CI; 0.06–0.11) of children with the TB cases, with a prevalence ranged from 3% (95% CI; 0.01–0.08) to 19% (95% CI; 0.07–0.43) in each study. Although the test for heterogeneity was not statistically significant (p = 0.080), the I² value of 40.15% suggests a moderate level of variability in the prevalence of RR-TB across the individual studies (Table 4). In this meta-analysis, the pooled prevalence of RR-TB in patients with PTB was computed from the findings of 18 individual studies [22–24, 27, 29, 33–35, 38, 41–43, 45, 50, 51, 53, 57, 58], and it was 8% (95% CI: 0.07–0.10). The prevalence of RR-TB in each study ranged from 2% (95% CI: 0.01–0.06) to 16% (95% CI: 0.13–0.20), with considerable heterogenicity (I2 = 81.97%, p < 0.001) across the individual studies. The combined prevalence of RR-TB in EPTB cases was determined by pooling data from six [22, 24, 33, 35, 46, 50] research papers. The results showed that, the pooled prevalence of RR-TB in EPTB cases was 9% (95% CI; 0.07–0.11) with the prevalence ranged from 3% (95% CI; 0.01–0.16) to 11% (95% CI; 0.09–0.14) across the individual studies. As shown in Table 4 below, the reported prevalence of RR-TB in EPTB cases did not differ between the individual studies (I2 = 0.00%, p = 0.520). In this meta-analysis, the data was extracted from 19 research papers [22, 25, 27–29, 32–36, 38, 41–43, 50, 53, 57, 58, 60] to determine the pooled prevalence of RR-TB among newly diagnosed TB cases and the results showed that it was 7% (95% CI: 0.06–0.09). The prevalence ranged from 1% (95% CI: 0.00–0.07) to 15% (95% CI: 0.12–0.17) with significant heterogenicity (I2 = 88.27%, p < 0.001) across the individual studies. Additionally, the pooled prevalence of RR-TB among TB cases who had previously received treatment was determined by combining data from 21 publications [22, 24, 25, 27–29, 32–36, 38, 41, 43, 45, 46, 50, 51, 53, 57, 60], and it was 17% (95% CI: 0.13–0.22). The prevalence varied from 5% (95% CI; 0.02–0.13) to 41% (95% CI; 0.35–0.47) within the individual studies (I2 = 82.44%, p < 0.001). As shown in Table 4 below, the occurrence of RR-TB was significantly varied among newly diagnosed and previously treated TB cases (p < 0.001). The pooled prevalence of RR-TB among TB-HIV cases In this meta-analysis, out of the total 39 research articles, the prevalence of RR-TB among TB-HIV cases was pooled from the data in 14 research articles [22, 24, 28, 29, 32–36, 38, 43, 50, 51, 57] (Fig. 5). As a result, the overall prevalence of RR-TB was found in 13% (95% CI: 0.08–0.18) of TB-HIV cases, and with a significant variation (I2 = 85.34%, p < 0.001), the prevalence in each research ranged from 3% (95% CI: 0.01–0.15) to 38% (95% CI: 0.31–0.46) (Table 4; Fig. 5).Fig. 5The pooled prevalence of RR-TB among TB–HIV co-infected patients from studies utilizing the GeneXpert MTB/RIF assay in Ethiopia The pooled prevalence of RR-TB among TB–HIV co-infected patients from studies utilizing the GeneXpert MTB/RIF assay in Ethiopia Quality, heterogeneity and publication bias of studies In this review, the quality of eligible studies was checked against items included in the Joanna Briggs Institute (JBI) quality appraisal tools (Supplementary file 3). Those studies fulfilling the criteria and those with sufficient information to meet out outcomes of interests were included for this systemic review and meta-analysis. Besides, the visual inspection of a funnel plot revealed that the included studies are scattered symmetrically with different numbers on each side of the central line, which is an indicator of the differences in the estimated prevalence of tuberculosis in the included studies (Fig. 6). The observed differences in the prevalence in the included studies is most likely not due to chance but might be due to the study methodology, sample types used, study periods, detection methods, and characteristics of the study populations. Begg’s and Mazumdar rank correlation tests indicated there was no publication bias in the included studies (Z = 1.53; Pz−value = 0.129). The Egger regression asymmetry test also indicates that the presence of publication bias in the studies was insignificant (t = 0.940; Pt = 0.354).Fig. 6Funnel plot indicating the presence of publication bias in the included studies Funnel plot indicating the presence of publication bias in the included studies Discussion TB remains a major health challenge in developing countries, where knowledge and information gaps persist. Thus, recent and comprehensive evidence syntheses are essential to guide policymakers and healthcare professionals in implementing effective TB prevention and control strategies. The overall pooled prevalence of TB in this meta-analysis was 15%, with a prevalence range of 3% to 47% across individual studies. This result was marginally higher than the pooled prevalence of TB in Ethiopia in a prior meta-analysis report, which was found to be 12.5% in average [61, 62]. The pooled prevalence of TB in Sudan was 30.7% [63], while in sub-Saharan Africa overall it was reported to be 27.4% [64], both of which are higher than our findings. The observed variation could be attributed to several factors, including the diagnostic techniques used to detect MTB. This meta-analysis included only studies that employed the GeneXpert MTB/RIF assay for MTB detection. Routine use of the GeneXpert MTB/RIF assay can be cost-effective and may enhance TB case detection, in addition to its advantage in identifying rifampicin-resistant TB cases [65, 66]. In Ethiopia, the GeneXpert MTB/RIF assay remains widely used across many healthcare settings, although some facilities have begun implementing the MTB/RIF Ultra assay, which offers improved sensitivity. A more serious feature of TB is the emergence and spread of DR-TB against two important first-line antibiotics, isoniazid, and rifampicin, which have always played a significant role in the prevention and control of TB infections [67, 68]. In this meta-analysis, the total pooled prevalence estimate of RR-TB was 8% with the prevalence varied greatly throughout studies. The observed variation in the reported rates of RR-TB may be attributed to the study’s region, study design, population groups, various detection techniques, the types of samples utilized, and TB prevention strategies. The overall result of this meta-analysis is consistent with those of prior meta-analyses finding in Ethiopia, in which the average pooled prevalence of RR-TB was reported to be 9.71% [69, 70]. As compared with other countries, the finding of this meta-analysis was in line with the data from Iran and Uganda, in which the pooled prevalence of RR-TB was 7.9% [71] and 7.0% [72], respectively. Consistent results were also reported by Salari et al. and Rostamian M et al., in which the global prevalence of RR-TB was found in 9.4% [73] and 7.3% [74] of TB cases, respectively. This result, however, is less than that of Sudan, which is 29.2% [75]. Only studies that utilized the GeneXpert MTB/RIF assay as the method of detection were included in this meta-analysis, which may not fully represent the overall prevalence of drug-resistant TB in Ethiopia. In addition, the retrospective nature of many included studies may introduce inherent biases such as incomplete data reporting, and variability in data quality and could influence the pooled estimates and limit the generalizability of the findings. The other report highlighted in this meta-analysis is the pooled prevalence of TB in general and RR-TB among newly diagnosed and previously treated TB cases. The meta-analysis revealed a higher prevalence of TB and RR-TB among previously treated cases compared to newly diagnosed individuals. The higher rate of resistance among previously treated TB cases was also reported in sub-Saharan Africa and Nigeria, where the pooled prevalence was 15% [76] and 53% [77], respectively, as compared with 2% and 32% among new TB cases. Several studies have also demonstrated that a prior history of tuberculosis therapy is a significant risk factor for developing DR-TB [78–81]. This risk may stem from noncompliance with first-line anti-TB treatment, besides having contact with a TB patient, contact with DR-TB patient, and different lifestyles such as alcohol abuse, smoking, and drug use are the major risk factors associated with the development of resistance to anti-TB drugs [79, 81]. Thus, early diagnosis of tuberculosis including universal drug-susceptibility testing, active screening of TB contacts and high-risk groups for drug-resistant TB, and improved adherence to anti-TB treatment may help detect DR-TB cases at an earlier stage and mitigate the further emergence and transmission of drug-resistant TB within the community. In this meta-analysis, similar to PTB, the pooled prevalence of EPTB was 15%. Likewise, the pooled prevalence of RR-TB was comparable between the two groups. The rate of RR among PTB cases in this study was slightly lower as compared with the rate in EPTB cases. The previous meta-analysis finding in Ethiopia showed that the pooled prevalence of EPTB was 39% [82] and the overall pooled prevalence of rifampicin resistance was 6% [83]. Rifampicin-resistant MTB among PTB patients in Nepal was 10.2% [84] and 11.6% in Upper Egypt [85]. In contrast to our findings, other meta-analyses confirmed that the prevalence of RR-TB among EPTB cases was lower than among those of PTB cases, and having PTB was found to be a risk factor for DR-TB [79, 86]. Due to the limited availability of data on the prevalence and risk factors of drug-resistant EPTB, physicians and other responsible bodies are often more aware of drug resistance primarily among patients with PTB. Therefore, the findings of this meta-analysis provide important evidence to help bridge existing knowledge and awareness gaps among clinicians and stakeholders, thereby supporting efforts to overcome the ongoing challenges in providing and accessing essential TB diagnostic services in our setting. TB can affect anyone, regardless of age or sex. In this meta-analysis, the pooled prevalence of TB was 15% in adults and 13% in children under 18 years of age, while the pooled prevalence of RR-TB was also 9% and 8%, respectively. A study in Ethiopia reported that the rate of DR-TB to at least one of the five first-line anti-TB drugs was 6.5% among children less than 15 years old [87]. The difference in the rate of TB between adults and children might be related to the challenges in the identification and diagnosis of TB cases in children as young children are less likely to be infected with TB and difficulties in obtaining appropriate samples [88–90]. The presence of RR-TB in both adults and children represents a major challenge to effective TB care, as do the poor outcomes experienced by individuals with drug-resistant tuberculosis. Hence, it is important to identify the most impactful and cost-effective prevention, diagnosis, and treatment approaches to facilitate the rapid detection and effective care for RR-TB cases both in adults and children in Ethiopia. In this review, the overall pooled prevalence of TB and RR-TB was 15% and 10% among males, and 13% and 9% among females, respectively. According to a report in a previous global systemic review and meta-analysis, male patients have a higher prevalence (12.7%) of RR-TB as compared to female patients (8.8%) [73]. Many studies confirmed that the prevalence of TB and RR-TB was much higher among males than females [82, 83, 90, 91]. This might be due to the fact that men may have more chances of being exposed to smoking, drinking alcohol, and drugs as compared to women, which makes them more susceptible to be infected with TB [79, 81–83]. The pooled prevalence estimates of TB in general and RR-TB among HIV-positive patients in this meta-analysis were 20% and 13%, respectively. A meta-analysis report in Ethiopia reported that the pooled prevalence of TB among HIV-positive patients was 15% [92]. The global rate of RR-TB among HIV-infected individuals was reported to be 15.9% [90]. It is well documented that HIV infection is one of the most important factors associated with the increased risk of TB and the emergence of DR-TB [81, 93, 94]. This is because HIV-infected patients are more vulnerable to infection with MTB due to their impaired immune status, which makes them take anti-TB drugs more frequently, and hence the rate of developing DR-TB and infection is higher among these patients [81, 94]. Hence, strengthening the provision of comprehensive care for all people with TB, with particular attention to people who are vulnerable or in vulnerable situations (e.g., People living with HIV), is essential. Limitations This review has summarized the findings of 39 published articles reported on the prevalence of TB in general and RR-TB in Ethiopia. The findings of this meta-analysis may be reduced because we only included those studies that utilized the GeneXpert-MTB/RIF assays as their detection methods, making it impossible to conclude the true burden of TB and DR-TB in Ethiopia. In addition, some studies did not provide categorical data for male and female, adults and children, and among TB-HIV cases and these could also reduce the results of this meta-analysis. The observed heterogeneity among studies, inclusion of studies published in English only, exclusion of potential unpublished data, and variation of quality of the primary studies may also have compromised findings of this meta-analysis. Additionally, although efforts were made to minimize bias through strict inclusion criteria and rigorous quality assessment, the retrospective nature of many of the included studies remains a potential limitation, which may introduce inherent biases such as incomplete data reporting, and variations in data quality. Using the Egger’s and Begg/Mazumdar tests to assess publication bias in prevalence studies has also certain limitations, as variations in reported prevalence may also reflect true epidemiological differences across settings rather than selective publication. Another limitation of this meta-analysis is the inconsistent definition of “children” across studies, with some using an age cutoff of 15 years and others 18 years, potentially introducing heterogeneity in age-related analyses. However, the findings are still significant because the rate of TB and RR-TB patients in the general population is very concerning. Conclusion This systematic review and meta-analysis revealed that both TB and RR-TB remain prevalent across different demographic groups in Ethiopia. The pooled estimates indicate a considerable burden of TB and RR-TB among key populations, particularly among previously treated and HIV-positive individuals. These findings highlight the ongoing public health challenge posed by TB and RR-TB and underscore the importance of strengthening surveillance, diagnostic coverage such as access to the GeneXpert-MTB/RIF assay, and reporting systems to better understand the magnitude and distribution of the disease. Continued research and evidence-based programmatic actions are essential to monitor trends and guide targeted TB control and prevention strategies in Ethiopia. Supplementary Information Supplementary Material 1. PRISMA checklist. Supplementary Material 1. PRISMA checklist. Supplementary Material 2. The forest output for each category meta-analysis that reported in table 3 and 4 of a manuscript. Supplementary Material 2. The forest output for each category meta-analysis that reported in table 3 and 4 of a manuscript. Supplementary Material 3. JBI Critical Appraisal Checklist for each study reporting prevalence data. Supplementary Material 3. JBI Critical Appraisal Checklist for each study reporting prevalence data. Supplementary Material 4. Supplementary Material 4. Supplementary Material 5. Supplementary Material 5.